Daymark Wealth Partners LLC Buys 540 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Daymark Wealth Partners LLC increased its stake in shares of Quest Diagnostics Incorporated (NYSE:DGXFree Report) by 2.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 20,549 shares of the medical research company’s stock after purchasing an additional 540 shares during the quarter. Daymark Wealth Partners LLC’s holdings in Quest Diagnostics were worth $2,833,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Quest Diagnostics by 8.7% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 6,921 shares of the medical research company’s stock worth $947,000 after buying an additional 556 shares during the period. Panagora Asset Management Inc. lifted its stake in shares of Quest Diagnostics by 97.5% during the 1st quarter. Panagora Asset Management Inc. now owns 7,878 shares of the medical research company’s stock worth $1,078,000 after purchasing an additional 3,889 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of Quest Diagnostics by 3.4% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,923 shares of the medical research company’s stock worth $2,179,000 after purchasing an additional 525 shares during the last quarter. Sei Investments Co. lifted its stake in shares of Quest Diagnostics by 21.9% during the 1st quarter. Sei Investments Co. now owns 191,048 shares of the medical research company’s stock worth $26,165,000 after purchasing an additional 34,364 shares during the last quarter. Finally, Aviva PLC lifted its stake in shares of Quest Diagnostics by 22.1% during the 1st quarter. Aviva PLC now owns 68,068 shares of the medical research company’s stock worth $9,316,000 after purchasing an additional 12,298 shares during the last quarter. Institutional investors own 87.76% of the company’s stock.

Insider Activity at Quest Diagnostics

In related news, Director Vicky B. Gregg sold 2,500 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $126.64, for a total value of $316,600.00. Following the completion of the sale, the director now owns 16,329 shares of the company’s stock, valued at $2,067,904.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 661 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $126.14, for a total transaction of $83,378.54. Following the completion of the sale, the senior vice president now owns 40,206 shares of the company’s stock, valued at $5,071,584.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Vicky B. Gregg sold 2,500 shares of Quest Diagnostics stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $126.64, for a total value of $316,600.00. Following the completion of the sale, the director now directly owns 16,329 shares of the company’s stock, valued at $2,067,904.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,150 shares of company stock valued at $1,913,202. 1.70% of the stock is currently owned by insiders.

Quest Diagnostics Stock Up 0.9 %

Shares of DGX stock opened at $128.28 on Monday. The stock’s 50-day simple moving average is $128.91 and its 200-day simple moving average is $130.13. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.20 and a current ratio of 1.31. The firm has a market capitalization of $14.20 billion, a PE ratio of 17.13, a P/E/G ratio of 2.79 and a beta of 0.90. Quest Diagnostics Incorporated has a fifty-two week low of $119.59 and a fifty-two week high of $148.62.

Quest Diagnostics (NYSE:DGXGet Free Report) last announced its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.15 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.04. The business had revenue of $2.29 billion for the quarter, compared to analyst estimates of $2.25 billion. Quest Diagnostics had a return on equity of 15.79% and a net margin of 9.23%. The company’s revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.98 earnings per share. Equities analysts expect that Quest Diagnostics Incorporated will post 8.75 earnings per share for the current year.

Quest Diagnostics Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 22nd. Stockholders of record on Monday, April 8th will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 2.34%. The ex-dividend date is Friday, April 5th. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.71. Quest Diagnostics’s dividend payout ratio (DPR) is 37.92%.

Analyst Upgrades and Downgrades

DGX has been the subject of a number of analyst reports. Bank of America upgraded Quest Diagnostics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $140.00 to $160.00 in a research note on Tuesday, December 12th. Citigroup upped their price objective on Quest Diagnostics from $130.00 to $145.00 and gave the stock a “neutral” rating in a research note on Monday, December 11th. Leerink Partnrs restated a “market perform” rating on shares of Quest Diagnostics in a research note on Monday, February 26th. SVB Leerink assumed coverage on Quest Diagnostics in a research report on Monday, February 26th. They set a “market perform” rating and a $135.00 target price on the stock. Finally, Truist Financial reduced their target price on Quest Diagnostics from $150.00 to $145.00 and set a “hold” rating on the stock in a research report on Friday, February 2nd. Ten research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Quest Diagnostics currently has an average rating of “Hold” and a consensus target price of $144.18.

Get Our Latest Stock Analysis on DGX

About Quest Diagnostics

(Free Report)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Further Reading

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXFree Report).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.